BioNano Genomics (NASDAQ:BNGO)‘s stock had its “buy” rating restated by analysts at Maxim Group in a research report issued on Friday, AnalystRatings.com reports. They presently have a $3.00 target price on the stock. Maxim Group’s price objective would indicate a potential upside of 240.91% from the company’s previous close.
Several other research firms have also weighed in on BNGO. ValuEngine raised BioNano Genomics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered BioNano Genomics from a “hold” rating to a “sell” rating in a research note on Monday, September 23rd.
NASDAQ:BNGO opened at $0.88 on Friday. The stock has a fifty day moving average price of $0.92 and a two-hundred day moving average price of $2.14. The company has a debt-to-equity ratio of 3.13, a quick ratio of 2.77 and a current ratio of 3.17. BioNano Genomics has a 1 year low of $0.50 and a 1 year high of $8.00. The stock has a market capitalization of $16.94 million, a price-to-earnings ratio of -0.34 and a beta of 1.06.
BioNano Genomics Company Profile
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Featured Story: Understanding Market Liquidity
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.